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Abstract Abnormal cytoplasmic mislocalization of transactive
response DNA binding protein 43 (TARDBP or TDP-43) in
degenerating neurons is a hallmark of amyotrophic lateral scle-
rosis (ALS) and frontotemporal lobar degeneration with
ubiquitin-positive inclusions (FTLD-U). Our previous work sug-
gested that nuclear factor kappa B (NF-κB) may constitute a
therapeutic target for TDP-43-mediated disease. Here, we inves-
tigated the effects of root extract of Withania somnifera
(Ashwagandha), an herbal medicine with anti-inflammatory
properties, in transgenic mice expressing a genomic fragment
encoding human TDP-43A315T mutant. Ashwagandha extract
was administered orally to hTDP-43A315T mice for a period of
8 weeks starting at 64 and 48 weeks of age for males and fe-
males, respectively. The treatment of hTDP-43A315T mice ame-
liorated their motor performance on rotarod test and cognitive
function assessed by the passive avoidance test. Microscopy ex-
amination of tissue samples revealed that Ashwagandha treat-
ment of hTDP-43A315T mice improved innervation at neuromus-
cular junctions, attenuated neuroinflammation, and reduced
NF-κB activation. Remarkably, Ashwagandha treatment re-
versed the cytoplasmic mislocalization of hTDP-43 in spinal
motor neurons and in brain cortical neurons of hTDP-43A315T
mice and it reduced hTDP-43 aggregation. In vitro evidence is
presented that the neuronal rescue of TDP-43 mislocalization
may be due to the indirect effect of factors released from
microglial cells exposed to Ashwagandha. These results suggest
that Ashwagandha and its constituentsmight represent promising
therapeutics for TDP-43 proteinopathies.
Keywords Amyotrophic lateral sclerosis .Withania
somnifera . TDP-43 . NF-κB.
Introduction
Transactive response DNA binding protein was originally de-
scribed as a regulatory element involved in modulating HIV-1
gene expression [1]. The 414 amino acid-containing protein
has a molecular weight of 43 kDa (hence it is commonly
referred to as TDP-43), and structurally consists of 2 RNA
recognition motifs, a nuclear localization sequence, a nuclear
export domain, and a glycine-rich C-terminal domain [2].
TDP-43 is predominantly a nuclear protein, even though it is
capable of shuttling between the nucleus and cytoplasm—a
process partly regulated by nuclear localization signal and
nuclear export signal motifs [3]. TDP-43 is a DNA/RNAbind-
ing protein and it is involved in regulating RNA transcription,
splicing, trafficking, and microRNA biogenesis [4]. Its in-
volvement in neurodegenerative disorders was first reported
in 2006 when hyperphosphorylated, ubiquitinated, and
cleaved C-terminal fragments of the protein were detected
from postmortem brain and spinal cord of patients suffering
from frontotemporal lobar degeneration with ubiquitin-
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positive inclusions (FTLD-U) and amyotrophic lateral sclero-
sis (ALS) [5, 6]. TDP-43 has been shown to be prone to
aggregation [7], and neuronal and glial TDP-43 inclusions
have since been reported from >95% of sporadic ALS cases.
Protein cleavage, aggregation, and neurotoxicity enhancing
mutations in the TARDBP have also been reported from both
familial and sporadic ALS cases [8].
Cellular levels of TDP-43 appear to be tightly regulat-
ed. The protein has the intrinsic property of autoregulating
its RNA level by binding with the 3' untranslated region
leading to the excision of an intron, thereby resulting in
its degradation by nonsense-mediated RNA decay [9, 10].
However, in some human patients it has been demonstrat-
ed that TDP-43 levels are elevated [11, 12], suggesting
that disease-associated TDP-43 aggregates disrupt its
self-regulation, thereby contributing to the pathogenesis.
Mislocalization of nuclear TDP-43 into the cytoplasm is
also an early event in disease pathology, resulting in neu-
rotoxicity [13]. However, whether nuclear depletion, con-
stituting a Bloss of function^ of the protein, or its accu-
mulation in cytoplasm constituting a Bnovel gain of toxic
function^ plays the key role in the disease has been a
matter of debate [13, 14]. Nonetheless, insights from
few recent studies favor the Bloss of nuclear function^
hypothesis [15–19].
In a previous study, we provided evidence that nuclear
factor kappa B (NF-κB) may constitute a therapeutic target
in ALS pathogenesis with TDP-43 deregulation. We
showed that TDP-43 binds to and acts as a coactivator of
the P65 subunit of NF-κB [12]. Postmortem spinal cord
samples from sporadic ALS cases exhibited elevated levels
of NF-κB mRNA when compared with age-matched con-
trols and the p65 NF-κB protein displayed abnormal nu-
clear localization in neurons. In addition, treatment of
transgenic mice expressing human TDP-43A315T mutant
with Withaferin A, a NF-κB inhibitor, ameliorated disease
phenotypes. Withaferin A is a component of the plant
Withania somnifera dunal [or Ashwagandha (ASH)], a pe-
rennial plant belonging to the family Solanaceae [20] that
has been in use for the last 4000 years in traditional Indian
medical system (Ayurveda). The root of the plant reported-
ly contains 14 to 15 different alkaloids and about 40 struc-
turally similar steroidal lactones (called withanolides) oth-
er than various carbohydrates and amino acids, in varying
amounts [21]. It reportedly has antimicrobial, anti-inflam-
matory, antineoplastic, antistress, cardioprotective, antidi-
abetic, and neuroprotective properties [22]. The neuropro-
tective property of the plant extract or purified products
from the plant has been demonstrated in multiple disease
models such as Alzheimer’s disease, Parkinson’s disease,
Huntington’s disease, and spinal cord injuries [23]. The
current study was designed to evaluate the efficacy of
Ashwagandha (ASH) root extract to ameliorate behavioral
and pathological phenotypes in a transgenic mouse model
of ALS/FTLD exhibiting TDP-43 proteinopathy [24].
Materials and Methods
Preparation of ASH Root Extract
Withania somnifera (ASH) root, rich in various withanolides
and alkaloids, was provided to us in dried powder form by
Valeant Pharmaceuticals International Inc (Quebec, Canada).
The product is an 11:1 extract from the plant root.
ALS/FTLD Mouse Model and Treatment Paradigm
A transgenic mouse line bearing human genomic fragment
encoding TDP-43 with A315T mutation was generated previ-
ously by us [24]. Animals were randomly distributed in either
ASH-treated (n = 28) or Vehicle (Veh)-treated (n = 24) groups.
The average age of the male mice at the beginning of treat-
ment was 445 ± 0.45 days and that of female mice was 338
± 3.2 days. Birth records of all the mice used for the experi-
ments are provided in Figure S1. Mice in the ASH group were
fed 5 mg root powder (by gavage) as a suspension in 200 μl
sterile buffered saline every alternate day, for 8 or 16 weeks.
Animals in the Veh group received equal volumes of buffered
saline only for the same durations. This treatment had no
effect on survival and body weight of the animals, and there
were no outward manifestation of deleterious side effects. The
Animal Care Ethics Committee of Université Laval approved
all in vivo experimental protocols. Experiments were carried
out in accordance with the Guide to the Care and Use of
Experimental Animals of the Canadian Council on Animal
Care.
Rotarod Performance Test
To test motor coordination in treated and untreated mice they
were allowed to run on an accelerating rotarod at 3 rpm speed
with 0.25 rpm/s acceleration. Mice were subjected to 3 trials
per session every week and the longest latency to fall from the
rotating rod was recorded. The maximum cut-off limit was set
for 3 min.
Passive Avoidance Test
One-trial passive avoidance test was performed as described
earlier [25], with minor modifications. The latency time for
mice to enter the dark compartment was measured, with a 5-
min cut-off.
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Immunofluorescence Microscopy and Image Analysis
Spinal cord and brain samples collected postsacrifice were
sectioned and subjected to immunofluorescent staining by
methods previously described [26]. Details of antibodies used
are provided in Table 1. Slides were visualized under a Zeiss
Apotome or Leica DM5000B microscope. To quantify nucle-
ar or cytoplasmic staining intensity, unprocessed single-
channel images were overlaid with 4,6-diamidino-2-
phenylindole (DAPI) with the help of Adobe Photoshop
CS5. The nuclear area was traced based on the DAPI signal
with the pencil tool followed by tracing of the entire cell body,
also with the pencil tool, but with a different color. All the cells
of interest were thus marked followed by removal of the DAPI
channel and the images were saved. Further analysis of im-
ages were carried out by following a protocol described else-
where [27], with minor modifications. Briefly, the images
were opened with ImageJ software and converted to 16-bit.
The regions of interest (already marked out in Photoshop)
were selected using the freeform select ion tool .
Measurement was set for integrated density from the
Analyze menu. Whole cell and/or its nuclear fluorescence
intensities were measured after correcting for background
fluorescence. Nuclear:cytoplasmic ratio or just nuclear fluo-
rescence intensity or overall fluorescence intensity was calcu-
lated from data generated from multiple sections.
Neuromuscular Junction Staining
Twenty-μm-thick cryosections of mouse gastrocnemius
muscle were used to stain for neuromuscular junctions
(NMJs). Presynaptic connections were stained using
neurofilament-H and synaptic vesicle protein 2 (SV2).
Tetramethylrhodamine-conjugated α-bungarotoxin
(1:100; Sigma-Aldrich, St. Louis, MO, USA) was used
to label acetylcholine receptors located at the subsynaptic
membrane. Montages of z-stack images were captured
using a Zeiss Apotome microscope and the images were
processed using ImageJ and Adobe Photoshop. NMJs
were classified as fully innervated, partially innervated,
or denervated, based on the extent of overlap of α-
bungarotoxin and neurofilament-H+SV2 staining.
Protein Extraction Protocols
Spinal cords were excised from anesthetized mice after perfu-
sion with ice-cold 0.9% saline. Whole protein lysates were
extracted by methods previously described [26]. Cytosolic
and nuclear fractions from cultured cells were also prepared
as per methods described elsewhere [28]. Purity of the frac-
tions was confirmed by the presence of cytosolic glyceralde-
hyde 3-phosphate dehydrogenase or nuclear P84 proteins.
Table 1 List of antibodies used for Western blots (WB) and immunofluorescence (IF)
Antibody against Dilution for WB Dilution for IF Company
Actin 1:10,000 Millipore (Temecula CA, USA)
Arginase 1 1:1000 Santa Cruz (Santa Cruz, CA, USA)
Cox-2 1:1000 Cell Signaling Technologies (Danvers, MA, USA)
Glyceraldehyde 3-phosphate dehydrogenase 1:2000 Santa Cruz
Glial fibrillary acidic protein 1:5000 1:300 Cell Signaling Technologies
Hemagglutinin antigen HA 1:1000 Roche Applied Sciences (Penzberg, Germany)
Human transactive response DNA binding
protein 43 (TDP-43; clone 2E2-D3)
1:1000 1:200 Abnova (Taipei City, Taiwan)
Iba-1 1:500 Wako Chemicals (Richmond, VA, USA)
IkBa 1:1000 Santa Cruz
Inducible nitric oxide synthase 1:1000 BD Biosciences (San Jose, CA, USA)
NeuN 1:500 Cell Signaling Technologies
Neurofilament-H 1:100 Millipore
Nuclear factor kappa B (NF-κB) 1:1000 Santa Cruz
P84 1:2500 Abcam (Cambridge, UK)
Pan-TDP-43 1:5000 Proteintech (Chicago, IL, USA)
Peripherin 1:5000 Millipore
Phospho-NF-κB (Ser 536) 1:250 Cell Signaling Technologies,
Synaptic vesicle protein-2 SV-2 1:25 Developmental Studies Hybridoma Bank
(Mt. Prospect, IA, USA)
Tumor necrosis factor-α 1:400 Abcam
Ym-1 1:500 Stem Cell Technologies (Vancouver, Canada)
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Immunoblot Analysis
Immunoblot analysis were performed from samples containing
equal amount of protein (quantified by Bio-Rad Protein assay;
Bio-Rad, Hercules, CA, USA) bymethods previously described
[26]. Details of antibodies used are represented in Table 1.
Generation of Stable NSC34-hTDPA315T Cell Line
For in vitro experiments, NSC34 (a murine neuroblastoma/
spinal cord hybrid) cell line was used. Mammalian expres-
sion vector plasmid pCMV–TDP-43 with point mutation
A315T and a HA tag was generated previously [12]. Cells
were transfected with the pCMV–TDP-43A315T plasmid
using Lipofectamine 2000 reagent (Life Technologies,
Carlsbad, CA, USA) and were subsequently selected in
Dulbecco’s modified eagle medium (DMEM) containing
375 μg/ml Geneticin (G418; Life Technologies). For fur-
ther experiments, selected clones were amplified, checked
for protein expression, and propagated. Prior to experimen-
tation, these cells were differentiated as per the published
protocol [29].
Luciferase Assay to Check p65 Activation in Microglia
Mouse microglial cell line BV2 was stably transfected with
pGL4.32[ luc2P/NF-κB–RE/Hygro] plasmid DNA
( P r o m e g a , M a d i s o n , W I , U S A ) . T h e
pGL4.32[luc2P/NF-κB–RE/Hygro] vector contains 5 cop-
ies of an NF-κB response element that drives transcription
of the luciferase reporter gene luc2P. The stable cell line
was maintained in DMEM supplemented with 10% fetal
bovine serium and 100 μg/ml hygromycin. Cells (5 × 104
per well) were seeded in 24-well plates. The cells were
stimulated with 100 ng/ml bacterial lipopolysaccharide
(LPS) for 3 h, after which the media was removed, wells
washed with 1× PBS, followed by cell lysis using Glo
Lysis buffer (Promega). Luciferase activity was measured
using the Bright-Glo Luciferase assay system (Promega),
according to the manufacturer’s instructions. To test the
efficacy of ASH on reducing LPS-induced P65 activity,
cells were treated with varying concentrations of ASH ex-
tract in dimethyl sulfoxide (DMSO; 1 μg, 10 μg, 100 μg,
250 μg, and 500 μg per ml) for 3 h post-LPS treatment,
followed by luciferase assay. Control studies were done
with cells treated with ASH alone. Results were expressed
as mean of luciferase activity/μg cellular protein from at
least 6 wells in each treatment condition.
Cell Survival Assay
Cell viability post-ASH treatment was assessed using [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium] MTS assay, as per the manufac-
turer’s instructions (Promega). BV2 was seeded onto 96-well
plates at a density of 104 cells/well. The treatment paradigm
was similar to that explained for luciferase assay.
Postincubation with MTS reagent, the absorbance, reflecting
the reduction of MTS by viable cells, was determined at
490 nm using an EnSpire 2300 Multilabel reader (Perkin
Elmer, Waltham, MA, USA). Values were expressed as a per-
centage relative to those obtained in controls.
To test the effect of ASH extract on viability of NSC34–
hTDP-43A315T, cells were seeded in a 96-well plate and sub-
sequently treated with 250, 100, 10, and 1 μg/ml ASH extract
for 6 h. Values were expressed as a percentage relative to those
obtained in controls.
In VitroModel of Inducing hTDP-43 Mislocalization
To induce mislocalization of nuclear TDP-43 into the cy-
toplasm in NSC34–hTDP-43A315T cells, cells were subject-
ed to excitotoxic (2 mM glutamate in buffer containing
125 mM NaCl, 10 mM CaCl2 5.9 mM KCl, 11.6 mM
HEPES, and 11.5 mM glucose; pH 7.4), inflammatory
[40 ng/ml of recombinant tumor necrosis factor
(TNF)-α], or oxidative stimuli (50 μM) for varying time
points [29]. Cells were collected, washed once in ice-cold
1× PBS, and subjected to fractionation for separation of
cytosolic and nuclear fractions as described above.
Fig. 1 Effective inhibition of nuclear factor kappa B (NF-κB) activity by
Ashwagandha (ASH) extract in mouse microglial BV2 cells and
modulation of cytokine/chemokine activity in primary microglia. No
significant alteration in BV2 cell survival was observed by addition of
lipopolysaccharide (LPS) or ASH extract in dimethyl sulfoxide (DMSO)
at varying concentrations (500, 250, 100, 10, and 1 μg/ml) (a). BV2 cells
were stably transfected with pGL4.32[luc2P/NF-κB–RE/Hygro] plasmid
carrying 5 copies of an NF-κB response element that drives transcription
of the luciferase reporter gene luc2P. When treated with bacterial LPS
(100 ng/ml) there was an approximately 3-fold increase in NF-κB
luciferase activity compared with nontreated controls. When LPS-
stimulated cells were further treated with varying concentrations of
ASH–DMSO extract, a significant reduction was observed in luciferase
activity at 500 and 250 μg/ml doses(b). Data were analyzed by 1-way
analysis of variance with Bonferroni’s multiple comparison test as the
post-test (***p < 0.001). Cytokines and chemokines secreted from
primary microglia post-LPS challenge and the effect of ASH treatment
was evaluated by commercially available array. The cytokines/
chemokines whose levels were found to be significantly modulated
were (c) FAS ligand, (d) interferon (IFN)-γ, (e) interleukin (IL)-1β (not
statistically significant), (f) IL-4, (g) IL-6, (h) IL-17A, (i) monocyte
chemoattractant protein-1 (MCP-1/CCL2), (j) macrophage
inflammatory protein (MIP)-1α and (k) MIP-1γ, (l) monokine induced
by IFN-γ (MIG), (m) the chemokine LIX, (n) regulated on activation,
normal T cell-expressed and secreted (RANTES), (o) soluble TNF
receptor 1 (R1), (p) soluble TNF receptor 2 (R2), and (q) chemokine (C
motif) ligand 1 (XCL1). Data are represented asmean ± SEMof cytokine/
chemokine levels normalized against positive controls. Values are
expressed as arbitrary units (*p < 0.05; **p < 0.01; ***p < 0.001). IOD
= integrated optical density; CTRL = control
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Immunoblotting was performed with the protein samples to
determine the level TDP-43 in each fraction. Untreated
NSC34–hTDP-43A315T served as control.
Effect of Microglia-Conditioned Media
on Glutamate-Stimulated NSC34–hTDP-43A315T
To test the role of soluble factors released from microglia
on TDP-43 distribution in NSC34–hTDP-43A315T cells,
BV2 cells were seeded at a density of 2 × 106 cells per
10-cm plate and cultured from 16–20 h in DMEM contain-
ing 10% FBS. Prior to treatment, the culture media was
replaced with serum-free DMEM. Subsequently, the cells
were treated with either LPS (100 ng/ml) or ASH
(250 μg/ml dissolved in DMSO) and incubated for 4 h at
37 °C. Control BV2 cells were treated with an equal vol-
ume of DMSO only. After 4 h the culture supernatant was
collected and centrifuged under sterile conditions at
2655 g for 5 min to precipitate cellular debris; this
served as the conditioned media. NSC34–hTDP-43A315T
cells that had been seeded separately into 3 other plates
had been treated with glutamate (as described above) al-
most at the same time as BV2 treatment. Prior to addition
of the conditioned media onto the NSC34–hTDP-43A315T
cells, their glutamate-containing media were removed,
plates were washed with sterile PBS, and finally incubated
with the BV2-conditioned media and some fresh serum-
free DMEM (at a ratio of 2:1) for 12 h. Postincubation,
cells were collected and subjected to nuclear cytosolic frac-
tionation. Subsequently, they were analyzed by immuno-
blotting to determine TDP-43 levels. As negative controls
for this experiment, glutamate-treated NSC34–hTDP-
43A315T cells were treated with BV2-conditioned media
that had been heated at 70 °C to denature any soluble fac-
tors that may have been contained in them.
Culture and Treatment of Primary Mouse Microglia
Primarymicroglia were cultured from the brains of pups (post-
natal day 6) of TDP-43A315T mutant mice. Brains were col-
lected and placed in ice-cold PBS. Following mechanical dis-
sociation, the brains were incubated in a 0.25% Trypsine-
EDTA solution (Sigma-Aldrich) containing 250 K U/ml
DNase I (Sigma-Aldrich). After centrifugation, the cell pellets
were placed in T-75 cm2 flasks (Sarstedt, Nümbrecht,
Germany) for 10 d at 37 °C, 5% CO2, in DMEM high-
glucose media with 10% fetal bovine serum and antibiotic
solution (Sigma-Aldrich). Genotyping carried out from tissues
of the pups confirmed the identity of each culture. At conflu-
ence, the wild-type (WT), as well as transgenic microglia,
were plated in 6-well plates at a concentration of 200,000
cells/well in serum containing media. Cells were incubated
with granulocyte colony-stimulating factor 24 h later to allow
adhesion. After 2 to 3 days cells were deemed suitable for
experimentation.
Prior to treatment, cells were transferred to serum-free me-
dia. Microglia from WT mice or transgenic TDP-43A315T
mice were challenged with LPS or DMSO for 6 h to elicit
cytokine/chemokine release. One set of WT microglia was
treated with LPS for 3 h followed by further addition and
incubation with ASH extract in DMSO (250 μg/ml) for 3 h
more. Postincubation, the media was collected, centrifuged at
1000 × g for 5 min to precipitate out any debris, and the resul-
tant media was used for estimation of cytokine/chemokine
release.
Cytokine Array
The cytokine expression profiles from primary microglia
at different treatment conditions were performed with
mouse cytokine antibody array kit (Raybio Mouse
Inflammation Antibody Array 1, Cat#AAM- INF-1;
RayBiotech, Norcross, GA, USA) as previously described
[26]. Cell culture media post-treatment were centrifuged
at 300 × g to remove cellular debris and incubated with
the array membranes overnight at 4 °C. After washing in
with the buffer provided with the kit, membranes were
incubated with biotin-conjugated antibodies overnight.
Signal detection was performed according to the
RayBiotech protocol, by exposing membranes to X-ray
film (Biomax MR1; #8701302; Kodak, Rochester, NY,
USA), and the obtained results analyzed using ImageJ
software. Data are expressed in arbitrary units relative
to appropriate positive controls.
Effect of Direct ASH Treatment on NSC34–hTDP-43A315T
Cells
To evaluate if ASH can directly affect TDP-43 re-distribu-
tion, NSC34–hTDP-43A315T cells were treated with ASH at
a concentration of 10 μg/ml, with or without glutamate
pretreatment. TDP-43 levels were determined by immuno-
blotting from nuclear and cytoplasmic fractions of these
cells.
Statistical Analysis
Prism 5.0 (GraphPad, La Jolla, CA, USA) was used for all
statistical analysis. Comparisons between 2 groups were done
by unpaired two-tailed t test with Welch’s correction.
Comparison between multiple groups was done by 1-way
analysis of variance with Bonferroni’s post-test. A p-value
up to 0.05 was considered significant.
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Results
ASH Extract Inhibits NF-κB Activation in Cultured Cells
To assess whether our ASH sample had the potency to
inhibit the NF-κB signaling pathway, we used mouse
microglial cells BV2 that were stably transfected with a
NF-κB P65–luciferase reporter. BV2 cells were found to
tolerate high doses of the ASH extract solubilized in
DMSO, and we found no significant cell death with up to
500 μg/ml of the drug (Fig. 1a). Exposure of the cells to an
inflammatory challenge (100 ng/ml Escherichia coli LPS)
led to a 3-fold increase in luciferase activity. When the
LPS-stimulated microglia were treated with varying con-
centrations of ASH (500, 250, 100, 10, and 1 μg/ml), there
was a dose-dependent decrease in luciferase activity
(p < 0.001) (Fig. 1b). We concluded that our ASH sample
had the potency to inhibit the NF-κB signaling pathway, a
potential therapeutic target in TDP-43-mediated neurode-
generative disease.
Modulation of Cytokine/Chemokine Profile of Stimulated
Primary Microglia Post-Treatment With ASH
In vitro, there was no significant difference between the secre-
tory cytokine/chemokine profiles of WT or TDP-43A315T mi-
croglia, with or without LPS challenge (Fig. S2a). On treating
WT microglia with LPS a significant upregulation was ob-
served in the levels of FAS ligand (2.68-fold), interferon-γ
(2-fold), interleukin (IL)-1β (2.06-fold; but not statistically
Fig. 2 Oral Ashwagandha (ASH) administration ameliorated
performance of hTDP-43A315T mice on rotarod and passive avoidance
tasks. ASH or vehicle (Veh)-treated male or female mice were trained
to run on an accelerating rotarod (speed 3 rpm; acceleration 0.2 rpm/s)
and the latency to fall was recorded. The maximum score of 3 trials for
each mouse is represented. A significant increase was observed in the
latency to fall in mice treated with ASH as compared with Veh-treated
controls from 5 weeks post-treatment onwards. Discontinuation of ASH
treatment resulted in gradual decrease in latency in both male and female
mice (a, b). Data were compared using an unpaired t test with Welch’s
correction (#p < 0.01; **p < 0.001; *p < 0.0001). After 8 weeks of
treatments, male (c) and female (d) mice were subjected to the passive
avoidance test to assess memory function based on the association
formed with an nociceptive stimulus. The results clearly demonstrated a
significant increase in memory retention in ASH-treated mice of either
sex in comparison to Veh-treated controls. These data were analyzed by
Kruskal–Wallis test with Dunn's multiple comparison post-test
(##p < 0.01)
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significant), IL-6 (13.8-fold), IL-17A (2.21-fold), monocyte
chemoattractant protein-1 (2-fold), macrophage inflammatory
protein (MIP)-1α (4.5-fold) andMIP-1γ (1.6-fold), monokine
induced by interferon-gamma (2.8-fold), the chemokine LIX
(4.68-fold), and regulated on activation, normal T cell
expressed and secreted (RANTES) (2.65-fold). On the con-
trary, IL-4 (0.52-fold) and chemokine (C motif) ligand 1 (0.6-
fold) levels were found to decrease significantly following
LPS challenge. However, ASH treatment of LPS-challenged
cells resulted in significant downregulation in the levels of the
upregulated cytokines/chemokines and upregulation of IL-4
and chemokine (C motif) ligand 1 levels. Interestingly, even
though the levels of soluble TNF receptor R1 and R2 levels
were found to be elevated after LPS challenge, there was no
significant alteration in the level of secreted TNF-α (data not
shown) (Fig. 1c–q).
Amelioration of Motor and Cognitive Performance
in Transgenic Mice Expressing hTDP-43A315T
A suspension of ASH root extract was prepared in buffered
saline at a concentration of 25 mg/ml of which 200 μl was
administered orally (gavage) to hTDP-43A315T every alternate
day (i.e., 5 mg/per animal at one time). The treatment lasted
for 8 weeks, beyond which it was continued in about 50% of
the animals and discontinued in the remaining half. Control
hTDP-43A315T mice received equal volumes of buffered sa-
line. When treated with ASH for a period of 8 weeks, the
hTDP-43A315T mice exhibited a significant increase in the
latency to fall in the accelerating rotarod test when compared
with Veh-treated hTDP-43A315T mice (p < 0.0001 for males;
p < 0.001 for females). Cessation of the treatment at 8 weeks
led to a gradual decrease of performance in rotarod test for
both male and female mice (p < 0.01 for both males and fe-
males; Fig. 2a, b). The difference observed in the latency to
fall between male and female Veh-treated animals seemed to
be due to the difference in their body weights. The mean body
weight of male animals was always in excess of 10 to 12 g
than that of the female animals, irrespective of treatment
(Fig. S2b). It should be noted that ASH treatment had no effect
on body weight in either male or female animals. Yet, in com-
parison to performance of nontransgenic animals (equal num-
ber of male and female with approximately equal body
weights and equivalent age as the TDP-43A315T animals) on
the accelerating rotarod (Fig. S2c), only ASH-treated female
mice could perform at the same level and only as long as the
treatment was continued.
To further evaluate the effect of ASH on cognitive perfor-
mance of hTDP-43A315T mice, we used the passive avoidance
test. ASH treatment of hTDP-43A315T mice increased signifi-
cantly the latency to enter the dark chamber, irrespective of sex
(Fig. 2c, d). In contrast, the Veh-treated hTDP-43A315T mice
were inept at recalling the unpleasant experience encountered
in the dark chamber, thereby indicating cognitive defects.
Improvement of NMJ Innervation in hTDP-43A315T Mice
Immunohistologic analysis of gastrocnemius muscle sections
to visualize NMJs revealed that in ASH-treated mice the num-
ber of innervated NMJs (complete + partial) was significantly
higher than in Veh-treated animals. ASH-treated animals had
significantly more number of innervated NMJs than denervat-
ed NMJs (p < 0.001). On comparing totally denervated NMJs,
it was observed that ASH-treated mice had significantly less
total denervated NMJs than Veh-treated mice (p < 0.001)
Fig. 3 Increase of innervated neuromuscular junctions (NMJs) in
Ashwagandha (ASH)-treated hTDP-43A315T mice. Serial sections of
gastrocnemius muscle of ASH- or vehicle (Veh)-treated hTDP-43A315T
mice were done with a cryostat. The sections were stainedwith antibodies
against neurofilament-heavy chain (NF-H) and synaptic vesicle
glycoprotein 2A (SV2) followed by Alexa-488 conjugated secondary
antibody. Prior to mounting, the sections were briefly incubated with α-
bungarotoxin conjugated with tetramethylrhodamine. The numbers of
innervated, partially innervated, or denervated NMJs were counted
based on the merged colored composite images of the sections (a). The
data are represented as percent of total NMJs counted (b). ASH-treated
mice possessed significantly more innervated NMJs than the Veh-treated
controls in which roughly 50% of NMJs were denervated. Data are rep-
resentative of total NMJs counted from 7 sections per mice, 3 mice
per group (n = 1062 for ASH; n = 1501 for Veh) and were analyzed for
statistics by 1-way analysis of variance with Bonferroni's multiple
comparison post-test (*p < 0.001)
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(Fig. 3a, b). Whereas Veh-treated hTDP-43A315T mice exhib-
ited ~50% denervation of NMJs, ASH-treated mice exhibited
only ~30% denervation of NMJs.
Attenuation of Neuroinflammation in hTDP-43A315T Mice
To assess the effect of ASH on astrogliosis, multiple spinal
cord sections from at least 3 hTDP-43A315T mice belonging to
each group were immunostained for glial fibrillary acidic pro-
tein (GFAP), an intermediate filament protein present in astro-
cytes. The results showed distinct astrocyte morphology in the
ASH- and Veh-treated spinal cord sections. Astrocytes in
ASH-treated mice were thinner with long processes
(Fig. 4a–c), whereas those in Veh-treated mice had thicker cell
bodies but short processes (Fig. 4d–f). GFAP signal intensity
analysis carried out from sections from both the groups of
animals showed significantly less GFAP expression in ASH-
treated mice compared with Veh-treated mice (p < 0.001)
(Fig. 4g). Western blots also showed higher expression of
GFAP in Veh-treated animals (Fig. 4o).
Morphologically, there was also a difference in microglial
phenotypes of spinal cords from ASH- and Veh-treated
hTDP-43A315T mice. Microglia, visualized by Iba-1 staining,
showed a more reactive phenotype in Veh-treated mice com-
pared with that in ASH-treated mice. Microglia in ASH-
treated mice showed small soma with distal arborization
(Fig. 4i–k); in contrast, microglia in Veh-treated mice showed
an increase in soma size with multiple short thick processes
branching out (Fig. 4l–n). Iba-1 signal intensity analysis also
corroborated a lesser intensity of staining in ASH-treated an-
imals (p < 0.05) (Fig. 4h). Ym-1 and arginase-1 are well-
reported phenotypic markers for M2a microglia. In our
Fig. 4 Attenuation of astrogliosis and microgliosis by Ashwagandha
(ASH) treatment. Spinal cord sections from ASH- and vehicle (Veh)-
treated hTDP-43A315T mice were immunostained for glial fibrillary
acidic protein (GFAP; astrocytic marker) or Iba-1 (microglial marker).
A marked difference in the phenotype of ASH-treated (a–c) and Veh-
treated (d–f) astrocytes were observed. Similarly, microglia also showed
decreased activation post-ASH treatment (i–k) as compared with Veh-
treated (l–n). All images are of 20× magnification. Scale bar = 20 μm.
The single-channel images are in grayscale so as to give better contrast.
The merged colored images are 150% enlargements. (Inset) A single cell
has been enlarged to 300%. Overall integrated density (IOD) analysis of
GFAP (g) and Iba-1(h) staining intensities revealed significant reduction
of 28% and 23%, respectively, in the spinal cord of ASH -treated mice.
Data are mean ± SEM of multiple sections of at least 3 animals per group.
Statistical significance was analyzed by 2-tailed t test with Welch’s cor-
rection (*p < 0.05; ***p < 0.001). Western blot analysis also clearly
showed more GFAP expression in the spinal cords of Veh-treated mice
vs that in ASH-treated mice (o). The expression levels of 2 M2a
microglial phenotypic markers (Ym-1 and arginase-1) were found to be
increased in the spinal cord of ASH-treated hTDP-43A315T mice when
compared with Veh-treated controls. However, the tumor necrosis factor
(TNF)-α levels remained the same in the 2 groups (o). DAPI = 4,6-
diamidino-2-phenylindole
Ashwagandha for Treatment of TDP-43 Proteinopathy
samples, we saw an increased expression of both of these
proteins in ASH-treated animals compared with Veh-treated
animals. However, we failed to detect any difference in the
levels of TNF-α, a secreted cytokine from type M1 and M2b
microglia (Fig. 4o).
Reduced p65 NF-κB Levels in the Spinal Cord
of hTDP-43A315T Mice
Spinal cord sections from both ASH- and Veh-treated
mice were immunostained for detection of phophorylated
p65 NF-κB. On comparing images, captured at same ex-
posure levels, results showed that the nucleus of neurons
in ASH-treated mice (Fig. 5a–d) yielded a lesser signal
than that observed in Veh-treated animals (Fig 5e–h).
Integrated density of the signal, analyzed from individual
neurons after background removal using Image J, showed
a significant increase in presence of phopho p65 NF-κB in
neuronal nuclei of Veh-treated mice (p < 0.001) (Fig. 5i).
Immunoblot analysis from spinal cord extract also showed
an increase in total p65 NF-κB protein in Veh-treated
mice (Fig. 5j).
Fig. 5 Reduction of p65 nuclear factor kappa B (NF-κB) activation in
spinal cord of Ashwagandha (ASH)-treated hTDP-43A315T mice. Spinal
cord sections from ASH- and vehicle (Veh)-treated hTDP-43A315T mice
were immunostained for detection of phophorylated p65 NF-κB. A
significantly weaker staining signal was observed in the nucleus of
neurons (including motor neurons) from the ASH-treated hTDP-
43A315T mice (a–d) compared with Veh-treated hTDP-43A315T mice (e–
h). All images are of 20× magnification. Scale bar = 20 μm. The single-
channel images are grayscale so as to give better contrast. The merged
colored images are 150% enlargements. (Inset) A single cell with
phosphoP65 staining has been enlarged to 300%. To further confirm
this, the nuclear signal intensities from neurons of both groups were
measured using ImageJ after demarcation of the nuclear area using 4,6-
diamidino-2-phenylindole (DAPI) in Adobe Photoshop (outline drawn in
blue). Upon comparison there was significantly lower intensity of nuclear
signal in ASH-treated mice than in Veh-treated mice (i). Data are mean ±
SEM of signal intensities per unit nuclear area from at least 6 sections per
mouse, 3 mice per group. Data were analyzed by 2-tailed t test with
Welch’s correction (***p < 0.001). Immunoblot performed from whole
spinal cord lysate also revealed lower expression levels of P65 NF-κB
protein in ASH-treated mice than in Veh-treated controls (j)
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Rescue of TDP-43 Mislocalization and Aggregation
Transgenic mice expressing hTDP-43A315T start exhibiting
mislocalization of TDP-43 into the cytoplasm of spinal motor
neurons at approximately 8 months of age. At 12 months of
age, almost all spinal neurons showed a lack of nuclear stain-
ing for hTDP-43 (Fig. 6a–d). On completion of the treatment
schedule after 8 weeks, the average age of the male mice was
of ~505 days and that of the female mice of ~398 days. Post-
ASH treatment, hTDP-43 protein was mostly detected in the
nucleus of spinal neurons (Fig. 6e–h), whereas hTDP-43 had a
diffused cytoplasmic localization in spinal neurons of Veh-
treated animals (Fig. 6i–l). A nuclear/cytoplasmic ratio of im-
munofluorescent signal from 21 lumber spinal cord sections
of 3 mice per group, analyzed using ImageJ software, showed
a significantly increased nuclear immunostaining of hTDP-43
(p < 0.001) (Fig. 6m). This redistribution was corroborated by
immunoblot data showing the presence of increased full-
length hTDP-43 (and the toxic 35-kDa cleaved fragment/
splice variant) in the detergent-insoluble fractions of spinal
cord of Veh-treatedmice comparedwith the ASH-treated mice
(Fig. 6n). In the brain, cortical neurons displayed similar re-
sults. In ASH-treated hTDP-43A315T mice, hTDP-43 had pre-
dominant nuclear localization in cortical neurons. Conversely,
in Veh-treated mice, hTDP-43 was predominantly cytosolic
(Fig. S2d, e).
Reduction of Peripherin Expression
The intermediate filament protein peripherin has been shown
to be involved in neurite elongation at developmental stage
and axonal regeneration but could also be responsible for
Fig. 6 Alleviation of human transactive response DNA binding protein
43 (hTDP-43) mislocalization and aggregation in Ashwagandha (ASH)-
treated hTDP-43A315T mice. In hTDP-43A315T mice, there is a clear
nuclear depletion of hTDP-43 occurring in spinal motor neurons at
about 11 months of age (a–d). Therefore, ASH treatment was initiated
after this age. After 8 weeks of treatment, the spinal cord of hTDP-
43A315T mice (~500 days old) exhibited intense immunodetection of
hTDP-43 in the nucleus of motor neurons (e–h). In contrast, the Veh-
treated mice exhibited diffused hTDP-43 in the cytoplasm of spinal cord
neurons (i–l). All images are of 20× magnification. Scale bar = 20 μm.
The single-channel images are grayscale so as to give better contrast. The
merged colored images are 150% enlargements. (Inset) A single cell with
hTDP-43 staining has been enlarged to 300%. Nuclear:cytoplasmic
hTDP-43 stain intensity was calculated from motor neurons (neurons
with diameter ≥4 μm) present in ventral horn of spinal cord sections
using ImageJ after demarcation of the nuclear (outline drawn in red)
and whole cell area (outline drawn in yellow) using 4,6-diamidino-2-
phenylindole (DAPI) in Adobe Photoshop. Results showed a significant
increase of about 3.5-fold in the nuclear to cytoplasmic ratio in ASH-
treated spinal motor neurons compared with Veh-treated samples (m).
Data were analyzed by 2-tailed t test with Welch’s correction
(***p < 0.001). On subjecting detergent-soluble and insoluble fractions
of spinal cord lysate to immunoblotting, no major difference was
observed in the soluble hTDP-43 levels between the 2 groups.
However, hTDP-43 was present at lower levels in the insoluble fraction
of ASH-treated hTDP-43A315T mice when compared with Veh-treated
hTDP-43A315T mice. ASH treatment caused also a reduction in levels of
the toxic 35-kDa TDP-43 species (cleaved fragment/splice variant) (n)
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protein aggregation and motor neuron death in ALS [42]. In
Veh-treated transgenicmice, peripherin was found to be prom-
inently expressed. However, in the spinal cord of hTDP-
43A315T mice treated with ASH, there was a marked reduction
in peripherin levels (Fig. S2f). Note that peripherin levels in
female hTDP-43A315T mice were higher than in male mice,
irrespective of the treatment.
Nuclear TDP-43 Redistribution in Cell Culture System is
Mediated by Secreted Factors From ASH-Treated
Microglial Cells
To further address whether the nuclear redistribution of TDP-
43 was due to a direct effect of ASH on neurons or indirect
effect via microglial cells, we used motor neuron-like cells
NSC34 that were stably transfected to express human TDP-
43A315T. TDP-43 was overexpressed in these cells by about
30% in comparison with nontransfected cells, as shown by
immunoblotting with pan TDP-43 antibody (p < 0.05)
(Fig. 7a, b). However, it was observed that the hTDP-
43A315T remained compartmentalized in the nuclear fraction
in unstimulated transgenic cells (Fig. 7c). To induce hTDP-43
mis-localization into the cytoplasm the transfected cells were
challenged with excitotoxic, oxidative, or inflammatory stim-
uli with 2 mM glutamate, 50 μMH2O2, and 40 ng/ml TNF-α,
respectively. Immunoblot analysis showed that TDP-43 was
detected in cytosolic fractions from both glutamate- and
TNF-α-treated transfected cells but not in H2O2-treated cells
(Fig. 7d). As the cytoplasmic levels of TDP-43 were higher
with glutamate treatment, further studies were conducted
using this paradigm. On culturing glutamate pretreated
NSC34–hTD-P43A315T cells in presence of conditioned media
from mock-treated or LPS-stimulated microglial cells, it was
observed that hTDP-43 could be detected in cytoplasmic frac-
tion. However, in cells cultured with conditioned media from
ASH-treated microglia, there was almost no detectable hTDP-
43 in the cytoplasmic fraction (Fig. 7e). Note that to generate
conditioned media, microglial cells were treated with
250 μg/ml ASH dissolved in DMSO. To confirm the role of
soluble factors released from microglial cells on this TDP-43
redistribution phenomenon, the same experiment was repeat-
ed with conditioned media which was first heated to 70 °C to
denature factors. Subsequent immunoblot analysis of cytosol-
ic and nuclear fractions showed uniform presence of hTDP-43
in cytosol of cells from all three groups, thereby suggesting a
disruption of the redistribution (Fig. 7f).
We further investigated whether there was a direct effect of
ASH on NSC34. On direct treatment of NSC34–hTDP-
43A315Twith 250 μg/ml ASH solution, almost 50% cell death
was observed just after 4 h of incubation. By reducing the dose
to 100 μg/ml no significant improvements were observed, but
on further lowering the concentrations (10 and 1 μg/ml) the
cells seemed to tolerate ASH (Fig. 7g). To test whether these
low ASH concentrations could affect P65 NF-κB activity in
NSC34–hTDP-43A315T cells, the P65 luc reporter was
transfected, as described in the BMaterials and Methods^ sec-
tion. The NSC34–hTDP-43A315T-P65 luc cells were then
treated with low dosage of ASH, with or without stimulation
with recombinant TNF-α. Luciferase assay from these cells
clearly showed that these doses were sufficient to reduce sig-
nificantly P65 activity post-TNF-α treatment (p < 0.01)
(Fig. 7h). Interestingly, it was also observed that direct ASH
treatment of glutamate-pretreated NSC34–TDP-43A315T cells
did not alter TDP-43 distribution (Fig. 7i).
Discussion
There is compelling evidence that the NF-κB signaling path-
way may represent a rational therapeutic target for ALS. For
instance, a number of ALS-linked genes encode proteins that
may interact with the NF-κB signaling pathway: 1) TDP-43
and FUS can bind and activate p65 NF-κB [12, 30]; 2) ALS-
linked mutations have been discovered in the optineurin gene,
Fig. 7 Evidence that nuclear redistribution of human transactive
response DNA binding protein 43 (hTDP-43) may result from soluble
factors released from microglia in response to Ashwagandha (ASH)
treatment. To study the role of microglial factors on TDP-43
redistribution in motor neurons in vitro, a model was devised wherein
motor neuron-like immortalized cell line NSC34 was stably transfected
with hTDP-43A315T-HA plasmid DNA (a). The stable cells showed about
30% increase in TDP-43 expression (b). Data were analyzed by t test with
Welch’s correction (*p < 0.05). hTDP-43 was found to be localized
predominantly inside the nucleus of these stably transfected cells (c).
Various treatments were tested for their potency to induce hTDP-43
cytoplasmic mislocalization. The cells were treated with either
glutamate (2 mM) or H2O2 (50 μM) or tumor necrosis factor (TNF)-α
(40 ng/ml). Glutamate was the most effective inducer of hTDP-43
mislocalization (d). Mouse microglial cell line BV2 was treated with
dimethyl sulfoxide (DMSO), lipopolysaccharide (LPS; 100 ng/ml), or
ASH (250 μg/ml) in solution in DMSO. The conditioned media from
these cells were used to treat glutamate-pretreated stably transfected
NSC34 cells. The conditioned media from BV2 cells induced
cytoplasmic mislocalization of hTDP-43 in NSC34 cells. However,
hTDP-43 was found to be cleared off from the cytosolic fraction of
NSC34 cells exposed to conditioned media from ASH-treated microglia
(e). Heat inactivation of the conditioned media prior to exposure to
NSC34 cells abolished the cytoplasmic clearance of hTDP-43 by media
of ASH-treated BV2 cells (f). The stably transfected NSC34 cells were
found to tolerate exposure to ASH solution poorly. On incubation with
250 and 100 μg/ml ASH, the viability of these NSC34 cells was
significantly reduced to 50% within 6 h. However, dosages of 10 and
1 μg/ml were found to be tolerated (g). Data were analyzed by 1-way
analysis of variance (ANOVA) with Bonferroni’s post-test (**p < 0.01).
The efficacy of 10 and 1 μg/ml doses of ASH on reduction of P65 activity
in stably transfected NSC34 cells were studied by luciferase assay.
Results showed that the 10 μg/ml was sufficient to significantly reduce
P65 activity post-TNF-α challenge (h). Data were analyzed by 1-way
ANOVA with Bonferroni’s post-test (***p < 0.05). However, ASH
treatment of NSC34 cells at 10 μg/ml failed to eliminate the cytosolic
mislocalization of hTDP-43 induced by glutamate (i). HA = Hemagglutinin
antigen ; GAPDH = glyceraldehyde 3-phosphate dehydrogenase
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which encodes a protein activating the suppressor of NF-κB
[31]; 3) mutations in valosin-containing protein activates
NF-κB signalling [32, 33]; 4) overt inflammation was present
in mice deficient for progranulin, a negative regulator of
NF-κB activity [34]; 5) p62 (SQSTM1) can be associated with
exacerbated inflammatory responses [35] and mutations in
ALS/FTLD increase p62 levels [36]; 6) NF-kB signaling path-
way is upregulated in ALS induced pluripotent stem cell-
derived motor neurons [37]; 7) ablation of NF-κB signaling
in microglia extended survival of superoxide dismutase 1 mu-
tant mice [38].
To attenuate activation of the NF-κB signaling pathway in
a transgenic mouse model of ALS, we tested an extract of
W. somnifera (ASH) that had the potency to reduce in a
dose-dependent fashion the activity of NF-κB P65–luciferase
reporter in the microglial cultured BV2 cells (Fig. 1). The anti-
inflammatory properties of ASH were further demonstrated
by it role in inhibiting proinflammatory cytokines/
chemokines released by primary mouse microglia as a result
of an inflammatory stimulus. Among the variety of cytokines
and chemokines affected, of particular interest are RANTES,
IL-6, IL-17, and MIP-1α, whose circulating levels in serum
and/or cerebrospinal fluid are reported to be elevated in ALS
[39–42]. Likewise, soluble TNF receptors R1 and R2 levels
are also reported to be elevated in plasma of patients with ALS
[43]. IL-4 levels have been reported to be negatively correlat-
ed with IL-6 levels in cerebrospinal fluid of ALS cases. Thus,
if IL-6 level increases, IL-4 decreases [44]. In vitro, ASH
restored LPS-induced downregulation of microglial IL-4 se-
cretion and thus may contribute to modulation of inflamma-
tory processes in multiple ways.
Transgenic mice expressing hTDP-43A315T genomic frag-
ment used in this study exhibited age-associated pathologic
changes, including TDP-43 proteinopathy, cognitive deficits,
and motor dysfunction [24]. When administered orally by
gavage in hTDP-43A315T transgenic mice >1 year of age,
ASH was found to ameliorate motor performance on rotarod
test, as well as cognitive function, as determined by passive
avoidance test. Moreover, ASH ameliorated muscle innerva-
tion, as well as pathological changes. Peripherin is an inter-
mediate filament protein whose accumulation is a pathologi-
cal hallmark of ALS and transgenic mouse studies demon-
strated that sustained peripherin overexpression can cause mo-
tor neuron death [45, 46]. Peripherin levels are upregulated in
the hTDP-43A315T transgenic mice [24], and ASH treatment
caused a marked reduction in peripherin levels.
Of particular interest was the finding that ASH led to re-
distribution of cytoplasmic hTDP-43 to the nucleus in spinal
motor neurons and in brain cortical neurons of TDP-43A315T
transgenic mice after 8 weeks of treatment (Fig. 6a–d,f,g ).
Moreover, ASH treatment reduced the levels of hTDP-43 re-
covered in the detergent-insoluble fraction of spinal cord
(Fig. 6e). Thus, ASH treatment may confer protection by
rescuing both the mislocalization and aggregation of hTDP-
43. It is noteworthy that ASH treatment led to a significant
reduction in levels of phospho-NF-κB in the nucleus of spinal
motor neurons of hTDP-43A315T mice (Fig. 5a–c). This obser-
vation provides further evidence of a link between inflamma-
tion and TDP-43 pathology. This is in line with our recent
report that chronic induction of inflammation by LPS treat-
ment exacerbated TDP-43 proteinopathy in hTDP-43A315T
mice [47].
The neuroprotective effects of ASH in this mouse model
led us to further investigate whether ASH exerted benefits
directly on neurons or indirectly on neurons via the action of
the compound on other CNS cell types like glial cells. To
address whether ASH may exert a direct protective effect on
neurons, we used NSC34 motor neuron-like cells that were
stably transfected to express hTDP-43A315T. Glutamate in-
duced excitotoxic stress and cytoplasmic mislocalization of
hTDP-43 in NSC34 cells. However, ASH treatment
at10 μg/ml did not rescue this phenomenon (Fig. 7i), but
treatment of glutamate-pretreated NSC34–hTDP-43A315T
cells with conditioned media from ASH-treated microglial
cells corrected the cytoplasmic mislocalization of hTDP-43.
The factors from ASH-treated microglia involved in hTDP-43
redistribution into nucleus were inactivated by heat (Fig. 7f).
Therefore, according to these in vitro results, the beneficial
effects of ASH on neuronal pathology likely arise indirectly
from the action of the drug on glial cells. Actually, it is well
established that glial cells contribute to the pathogenesis of
ALS [48]. Astrocytes have been reported in multiple studies
to be implicated in inducing motor neuron death [49, 50]. Yet,
astrocyte activation in response to factors released from dam-
aged motor neurons may also trigger the release of nerve
growth factor and other antioxidative enzymes that confer
neuroprotection [51]. The role of microglia is also complex.
In response to neurodegeneration or to accumulations of
misfolded proteins, microglia can proliferate and adopt an
activated state with secretion of several factors that may be
either beneficial or detrimental to neurons [52, 53]. Hence,
microglial responses can vary from neuroprotective (M2a
state) to injurious/toxic states (M1, classically activated)
[54]. In our study, after 8 weeks of ASH treatment, we ob-
served a significant reduction in GFAP expression in the spi-
nal cord of hTDP-43A315T mice, as well as reduction of Iba-1
immunoreactivity in microglia, although many of these cells
did not assume a quiescent morphology after ASH treatment.
Immunoblotting of spinal cord extracts revealed an upregula-
tion in levels of YM-1 and arginase-1, which are markers of
microglial M2a phenotype.
In conclusion, our results demonstrated beneficial effects of
ASH treatment on behavioral and pathologic phenotypes of
transgenic mice expressing hTDP-43A315T. It remains to be
determined what components in ASH are responsible for the
therapeutic effects. One active molecule in ASH is Withaferin
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A, a steroid lactone known to act as NF-κB inhibitor and
which has been shown to confer protection in 2 different
mouse models of ALS [12, 26]. Nonetheless, other compo-
nents present in ASHmay also confer protection. For instance,
sominone, a metabolite of withanoside IV has been shown to
promote neurite outgrowth and to improve learning and mem-
ory deficits in mice [55]. An extract ofW. somnifera was also
effective in reversing behavioral deficits and amyloid plaque
burden in a mouse model of Alzheimer’s disease [56]. In
addition to diseases of the ALS/FTLD spectrum, TDP-43 pa-
thology has been reported in other neurologic disorders in-
cluding Alzheimer’s disease, Parkinson’s disease, Lewy body
disease, cerebral ischemia, and hippocampal sclerosis [57].
ASH is a natural health product, easily accessible, and has
been well tolerated in previous studies. Nonetheless, there
are some drawbacks to such a therapeutic approach. As with
other plant extracts, it is still not clear which components of
ASH are responsible for what specific beneficial effects and
whether the benefits are due to compounds acting alone or
synergistically with others in whole extracts. Moreover, huge
variations in composition of ASH extracts may occur as a
result of variations in the source of W. somnifera or methods
of root extract preparations. Based on the findings presented
here, it is of interest to further investigate whether ASH extract
or it constituents might be effective in conferring therapeutic
effects in TDP-43 proteinopathies like ALS and FTLD.
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